Result: A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT

*Title*:

*Author/editor-in-chief*:

*Published in*:

Cancers. - Basel : MDPI, 20.06.2022. - Seiten 1-13. - 10.3390/cancers14123031. - ISSN 2072-6694. - Jahrgang 14, Heft 12, Artikel 303

*Publication*:

Basel : MDPI, 20.06.2022

*Distribution*:

Frankfurt am Main : Universitätsbibliothek Johann Christian Senckenberg

*Physical description scale*:

1 Online-Ressource (13 Seiten)

*Format*:

*eBook*

*Language*:

*eng*

*DOI*:

10.3390/cancers14123031

*oa_rights*:

Open Access
CC BY 4.0

*Result*: A novel 2-metagene signature to identify high-risk HNSCC patients amongst those who are clinically at intermediate risk and are treated with PORT